Patients with cystic fibrosis (CF) are repeatedly exposed to antibiotics, especially during the
pulmonary exacerbations of the disease. However, the available therapeutic strategies are …

Cystic fibrosis (CF) is an inherited multisystem disease affecting the lung which leads to a
progressive decline in lung function as a result of malfunctioning mucociliary clearance and …

Therapeutic drug monitoring (TDM) is a critical clinical tool used to optimize the safety and
effectiveness of drugs by measuring their concentration in biological fluids. These fluids are …

Background Cystic fibrosis transmembrane conductance regulator (CFTR) modulator
therapy have resulted in longer life expectancies, yet pulmonary exacerbations remain a …

The phenomenon of antimicrobial resistance (AMR) is a critical global health challenge, with
prospects indicating its potential to become the leading cause of death worldwide in the …

The chronic airway infection and inflammation characteristic of cystic fibrosis (CF) ultimately
leads to progressive lung disease, the primary cause of death in persons with CF (pwCF) …

The rapid pace of recent advancements in CF has led to significant improvements in patient
outcomes and has created new opportunities to personalize care decisions. Numerous …

The new breakthrough cystic fibrosis (CF) drug combination of ivacaftor (IVA), tezacaftor
(TEZ), and elexacaftor (ELX), namely “caftor” drugs, directly modulates the activity and …

Multidrug resistant (MDR) P. aeruginosa accounts for 35% of all P. aeruginosa isolated from
respiratory samples of patients with cystic fibrosis (CF). The usefulness of β-lactam …

Background Children with cystic fibrosis (CF) pulmonary exacerbations receive IV
tobramycin therapy, with dosing guided by either log-linear regression (LLR) or Bayesian …